For readers interested in the PDF version, the document is available for downloading or viewing:
2012-2013 FluWatch report: December 30, 2012 to January 11, 2013 (Week 1) (PDF Version - 113 KB - 6 pages)
»» Help with PDF documents
Overall Influenza Summary
In week 01, 15 regions [in BC(2), AB(2), MB(1), ON(5), QC(2) and NL(3)] reported widespread activity and 20 regions [in BC(3), AB(3), SK(2), MB(3), ON(2), QC(3), NB(2), and NS(2)] reported localized activity (Figures 1 and 2). In week 01, 107 new influenza outbreaks were reported: 88 in long-term-care facilities, 5 in hospitals, one in a school, and 13 in other facilities or communities (Figure 3).
Note: Influenza activity levels, as represented on this map, are assigned and reported by Provincial and Territorial Ministries of Health, based on laboratory confirmations, sentinel ILI rates (see graphs and tables) and reported outbreaks. Please refer to detailed definitions on the last page. For areas where no data is reported, late reports from these provinces and territories will appear on the FluWatch website.
The percentage of positive influenza tests decreased slightly from 34.5% in week 52 to 32.4% in week 01 (Figure 4). Among the influenza viruses detected in week 01 (n=3864), 98.1% were positive for influenza A viruses [of which 25.7% were A(H3), 1.1% were A(H1N1)pdm09, and 73.2% were A(unsubtyped)]; and 1.9% were positive for influenza B (Table 1). Cumulative influenza virus detections by type/subtype to date are as follows: 97.5% influenza A [33.2% A(H3), 1.2% A(H1N1)pdm09 and 65.6% A(unsubtyped)] and 2.5% influenza B (Table 1).
Detailed information on age and type/subtype was received for 10,867 cases to date this (Table 2). The proportions of cases by age group were as follows: 13.1% were < 5 years; 8.1% were between 5-19 years; 15.6% were between 20-44 years; 16.3% were between 45-64 years of age; 46.9% were ≥ 65 years.
The percentage of tests positive for RSV decreased slightly from 11.5% in week 52 to 10.2% in week 01. The percentage of tests positive for rhinovirus declined to 3.3% in week 01. Parainfluenza declined to 2.0% while coronavirus detections increased to 3.0% in week 01. Other percentages of positive tests remained low in week 52: adenovirus 0.6%; hMPV 0.8% (Figure 5). For more details, see the weekly Respiratory Virus Detections in Canada Report.
(December 30, 2012 to January 5, 2013)
(August 26, 2012 to January 5, 2013)
|A Total||A(H1)||A(H3)||Pand H1N1||A
( Un S)Table 1 note*
|Total||A Total||A(H1)||A(H3)||Pand H1N1||A
(Un S) Table 1 note*
|* Unsubtyped: The specimen was typed as influenza A, but no test for subtyping was performed. Specimens from NT, YT, and NU are sent to reference laboratories in other provinces. Note: Weekly data is based on week of positive lab detection. Cumulative data includes updates to previous weeks; due to reporting delays, the sum of weekly report totals do not add up to cumulative totals.|
(December 30, 2012 to January 5, 2013)
(August 26, 2012 to January 5, 2013)
|Influenza A||B||Influenza A||B|
|A Total||Pandemic H1N1||A/H3N2||A unsubtyped||Total||A Total||Pandemic H1N1||A/H3N2||A unsubtyped||Total|
|* Please note that this table reflects the number of specimens for which demographic information was reported. These represent a subset of all positive influenza cases reported. Delays in the reporting of data may cause data to change retrospectively.|
Figure 4. Influenza tests reported and percentage of tests positive, Canada,
by report week, 2012-2013
During the 2012-13 season, the National Microbiology Laboratory (NML) has antigenically characterized 193 influenza viruses [143 A(H3N2), 25 A(H1N1)pdm09 , and 25 influenza B]. The 143 influenza A(H3N2) viruses were antigenically similar to the vaccine strain A/Victoria/361/2011. The 25 A(H1N1)pdm09 viruses were antigenically similar to the vaccine strain A/California/07/09. Among the influenza B viruses, 21 were antigenically similar to the vaccine strain B/Wisconsin/01/2010 (Yamagata lineage) and four were similar to B/Brisbane/60/2008 (Victoria lineage; component of the 2011-2012 seasonal influenza vaccine) (Figure 6).
Note:The recommended components for the 2012-2013 Northern Hemisphere influenza vaccine include: an A/Victoria/361/2011 (H3N2)-like virus; an A/California/7/2009 (H1N1)pdm09-like virus; and a B/Wisconsin/1/2010-like virus.
During the 2012-13 season, NML has tested 178 influenza viruses for resistance to oseltamivir, and 176 influenza viruses for resistance to zanamivir. All viruses tested were sensitive to oseltamivir and zanamivir. A total of 243 influenza A viruses were tested for amantadine resistance and all were resistant (Table 3).
|Virus type and subtype||Oseltamivir||Zanamivir||Amantadine|
|# tested||# resistant (%)||# tested||# resistant (%)||# tested||# resistant (%)|
|* NA - not applicable|
|A (H3N2)||137||0||135||0||225||225 (100%)|
|B||23||0||23||0||NA *||NA *|
The national influenza-like-illness (ILI) consultation rate decreased from 67.1 ILI consultations per 1,000 patient visits in week 52 to 58.7 in week 01. This rate is above the expected level for this time of year, which is between 27.5 and 57.3 ILI consultations per 1,000 visits (Figure 7). In week 01, the highest consultation rates were observed in children 5-19 years of age (95.5/1,000) followed by children <5 years of age (94.1/1,000).
Figure 7. Influenza-like illness (ILI) consultation rates, Canada, by report week, 2012-2013 compared to 1996/97 through to 2011/12 seasons (with pandemic data suppressed)
Note: No data available for mean rate in previous years for weeks 19 to 39 (1996-1997 through 2002-2003 seasons). Delays in the reporting of data may cause data to change retrospectively.
The Canadian antiviral prescription rate continued to increase from 303.3 antiviral prescriptions per 100,000 new prescriptions dispensed in week 52 to 335.8 in week 01. Rates of 50-100/100,000 were observed during the peak period during the 2011-12 influenza season, when the percentage of positive influenza tests was between 18%-24% (data from April 2011 to present). Although the current proportion of antiviral prescriptions of 335.8/100,000 is higher than the peak observed last year, it continues to follow the trend of an increasing percentage of positive laboratory tests for influenza. In week 01, the antiviral prescription rate increased for adult and senior age groups, and decreased for infants and children. The highest rate was observed among seniors ≥65 years, at 667.3/100,000.
Note: Pharmacy sales data are provided to the Public Health Agency of Canada by Rx Canada Inc. and sourced from major retail drug chains representing over 3,000 stores nationwide (excluding Nunavut) in 85% of Health Regions. Data provided include the number of new antiviral prescriptions (for Tamiflu and Relenza) and the total number of new prescriptions dispensed by Province/Territory and age group.
Paediatric Influenza Hospitalizations and Deaths (IMPACT)
In week 01, 69 new laboratory-confirmed influenza-associated paediatric (16 years of age and under) hospitalizations were reported by the Immunization Monitoring Program Active (IMPACT) network: 2 from BC, 9 from AB, 2 from SK, 2 from MB, 21 from ON, 31 from QC and 2 from NL. Among the 66 cases identified with influenza A, 60 (90.9%) were A(unsubtyped), 4 (6.1%) were A(H3N2) and 2 (3.0%) were A(H1N1)pdm09. Three cases were identified with influenza B. The age distribution is as follows: 26 cases (37.7%) under 6 months of age, 12 (17.4%) between 6-23 months, 19 (27.5%) aged 2-4 years, 9 (13.0%) aged 5-9 years, and 3 (4.3%) aged 10-16 years. Four ICU admissions were reported during this week, one case between 6-23 months, two aged 2-4 years, and one aged 5-9 years.
Since the start of the 2012-13 season, a total of 342 influenza-associated paediatric hospitalizations have been reported by the IMPACT network: 330 (96.5%) with influenza A [of which 50 (15.2%) were A(H3N2), 2 (0.6%) were A(H1N1)pdm09 and 278 (84.2%) were A(unsubtyped)], and 12 (3.5%) with influenza B. The distribution of cases by age group is as follows: 77 (22.5%) <6 months of age, 69 (20.2%) age 6-23 months, 96 (28.1%) age 2-4 years, 62 (18.1%) age 5-9 years, and 38 (11.1%) age 10-16 years. Thirty-one of the 342 cases (9.1%) were admitted to the ICU. No deaths have been reported to date.
Note: The number of hospitalizations reported through IMPACT represents a subset of all influenza-associate paediatric hospitalizations in Canada.
Adult Influenza Hospitalizations and Deaths (PCIRN)
In week 01, 26 new laboratory-confirmed influenza-associated adult (16 years of age and older) hospitalizations were reported by the PHAC/CIHR Influenza Research Network (PCIRN) Serious Outcomes Surveillance (SOS) network: 1 from AB, 1 from MB, 13 from ON, 7 from QC, 2 from NB and 2 from NS. The age distribution is as follows: 19 cases (73.1%) were ≥65 years of age, 5 cases (19.2%) were aged 45-64 years, and 2 cases (7.7%) were aged 20-44 years. Among the 25 cases identified with influenza A, 4% (1/25) were A(H3N2) and 96% (24/25) were A(unsubtyped). One case was identified with influenza B. One ICU admission was reported during the current week in a case ≥65 years of age with influenza A(unsubtyped). One death was reported in a case ≥65 years of age with influenza A(unsubtyped).
From November 4, 2012 to January 5, 2013, a total of 232 influenza-associated adult hospitalizations have been reported by PCIRN-SOS network: 220 (94.8%) with influenza A [of which 29 (13.2%) were A(H3N2), 2 (0.9%) were A(H1N1)pdm09 and 189 (85.9%) were A(unsubtyped)]; 4 (1.7%) with influenza B and 8 (3.4%) were unknown. The distribution of cases by age group is as follows: 156 cases (76%) were ≥65 years of age, 53 cases (22.8%) were aged 45-64, 20 cases (8.6%) were aged 20-44 and 3 cases (1.3%) were aged <20 years. Twelve of the 232 cases (5.2%) were admitted to the ICU. Six deaths have been reported to date, all in cases with Influenza A(unsubtyped). Five deaths were in adults ≥65 years of age, and one was in a person 20-44 years of age.
Note: The number of hospitalizations reported through PCIRN represents a subset of all influenza-associate adult hospitalizations in Canada.
Provincial/Territorial Influenza Hospitalizations and Deaths (Aggregate Surveillance System*)
In week 01, 298 laboratory-confirmed influenza-associated hospitalizations were reported. Half of the cases (54% 162/298) were ≥65 years of age. Type and subtype information was available for 252 of the 298 cases. Of these 252 cases, the majority (96.4% 243/252) were influenza A and 3.6% (9/252) were influenza B. Of the 243 influenza A associated hospitalizations, 51.4% (125/243) were A(H3), 2.1% (5/243) were A(H1N1)pdm09 and the remaining were A(unsubtyped). Of the 138 cases with available data, 14.5% (20/138) were admitted to the Intensive Care Unit (ICU). Fourteen deaths were reported in week 01, all but one in persons ≥65 years of age. One death was reported in a case aged 0-4 years with influenza A. The cause of death does not have to be attributable to influenza, a positive laboratory test is sufficient for reporting. Detailed clinical information (e.g. underlying medical conditions) is not known for these cases.
To date this season, 885 influenza-associated hospitalizations have been reported from all participating provinces. Half of the cases (51.3% 454/885) were ≥65 years of age, 16.9% (150/885) were adults aged 45-64 years and 15.1% (134/885) were children aged 0-4 years. Type and subtype information was available for 839 cases. Of these, 97% have been influenza A, predominately A(H3). Among the 287 cases with available data, there have been 45 hospitalisations for which admission to ICU was required, 14 (31.1%) were persons ≥65 years of age and 15 (33.3%) were in persons aged 45-64 years. To date this season, 51 deaths have been reported: 90.2% (46/51) were persons ≥65 years of age, 3.9% (2/51) were adults aged 20-44 years, and 5.9% (3/51) were children aged 0-4 years. The cause of death does not have to be attributable to influenza, a positive laboratory test is sufficient for reporting. Detailed clinical information (e.g. underlying medical conditions) is not known for these cases.
* Note: The number of influenza-associated hospitalizations reported by the Aggregate Surveillance System may include cases reported by the IMPACT network. Note that the cause of death does not have to be attributable to influenza, a positive laboratory test is sufficient for reporting. Influenza-associated hospitalizations are not reported to PHAC by the following Provinces and Territory: BC, NU, QC, NS, and NB. Only hospitalizations that require intensive medical care are reported by SK. ICU admissions are not reported in ON.
WHO: As of 4 January 2013, influenza detections declined in many countries despite rising influenza activity reported in the northern temperate regions of North America, North Africa, eastern Mediterranean and Asia. This may have been due to reduced reporting during the holiday weeks. The start of the influenza season has been declared in northern China. Influenza activity in Europe has increased, mainly the northern and western regions. In central America, the Caribbean and tropical regions of south America, influenza activity continues to decline following the peak in late summer, with low levels of A(H3N2) and influenza B detected. The exception is Bolivia where A(H3N2) continues to circulate. Most countries in Sub-Saharan Africa report declining detections of influenza, except in Ghana and the Democratic Republic of Congo. In South East Asia, influenza circulation was similar to previous weeks with continued low-level circulation. Influenza in temperate regions of the southern hemisphere continues at inter-seasonal levels.
United States: During week 01, influenza activity remained high in the United States, but may be declining in some areas. Forty-seven states reported widespread influenza activity, two states reported regional influenza activity, and the District of Columbia reported local activity. The national percentage of outpatient visits for ILI is 4.3% which is above the national baseline of 2.2%. Nine of 10 regions reported ILI above region-specific baseline levels, and New York City and 24 states experienced high ILI activity in week 01. The proportion of tests positive for influenza viruses was 32.8% in week 01. Of the positive influenza detections, 79.8% were positive for influenza A viruses. Of the 1819 influenza A viruses for which subtype information was available, 98.0% were A(H3) and 2.0% were A(H1N1)pdm09. Since October 1, 2012, the CDC has antigenically characterized 521 influenza viruses. Among influenza A viruses, 327 were A/Victoria/361/2011-like, two (0.6%) of which showed reduced titers; and 17 were A/California/7/2009-like. Among influenza B viruses, 118 (66.7%) B/Wisconsin/01/2010-like belong to the Yamagata lineage of viruses; and 59 (33.3%) to the B/Victoria lineage. Two new influenza-associated paediatric deaths were reported during week 01. Twenty cases have been reported to date this season, 13 with influenza A and 7 with influenza B.
Europe: In week 01, widespread activity is reported in the northern and western regions, where consultation rates for ILI and ARI (acute respiratory infection) continue to rise. Lower activity is reported in eastern regions. There is continued co-circulation of A(H1N1)pdm09, A(H3N2) and influenza B, although the proportion of A(H1N1)pdm09 is increasing compared to A(H3N2). Since week 40, 9676 specimens of influenza viruses have been typed: 64% were influenza A and 36% were influenza B. Among the 2502 influenza A viruses for which subtype information was available, 42% were A(H3) and 58% were A(H1N1)pdm09. This is a significantly greater proportion of A(H1N1)pdm09 compared to the same period last season, when A(H1N1)pdm09 was detected in <5% of subtyped influenza A viruses. The number of hospitalizations due to severe acute respiratory illness (SARI) remains stable, with 8% associated with influenza detection in week 01.
Human Avian Influenza
No new WHO report of Influenza at the Human-Animal Interface has been published since 17 December 2012.
Human Swine Influenza
No new human cases of infection with swine influenza viruses or variants were reported in week 01.
FluWatch reports include data and information from the following sources: laboratory reports of positive influenza tests in Canada (National Microbiology Laboratory), sentinel physician reporting of influenza-like illness (ILI), provincial/territorial assessment of influenza activity based on various indicators, including laboratory surveillance, ILI reporting, and outbreaks, influenza-associated paediatric and adult hospitalizations, antiviral sales in Canada, and WHO and other international reports of influenza activity.
Abbreviations: Newfoundland/Labrador (NL), Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), Saskatchewan (SK), Alberta (AB), British Columbia (BC), Yukon (YT), Northwest Territories (NT), Nunavut (NU).
Note: ILI data may be reported through sentinel physicians, emergency room visits or health line telephone calls.
* More than just sporadic as determined by the provincial/territorial epidemiologist.
† Influenza surveillance regions within the province or territory as defined by the provincial/territorial epidemiologist.
We would like to thank all the Fluwatch surveillance partners who are participating in this year's influenza surveillance program.